Prevent Nigerian Mothers from Dying in Childbirth
|
Updates from the Field:
Updates from the Field (or Progress Reports) on GlobalGiving are posted directly to globalgiving.com by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
|
Keep Up-to-Date
 Subscribe to "Updates from the Field" by E-Mail
 Subscribe to "Updates from the Field" by RSS Feed
Index of Updates from the Field
Nigerians Approve New Misoprostol Clinical Guidelines
By Amy Grossman - Communications Manager, August 15, 2007 10:24 PM
Following our active involvement in achieving the world's first regulatory approval of misoprostol for postpartum hemorrhage, Venture Strategies for Health and Development assisted in the preparation of the misoprostol clinical guidelines for physicians and nurses in Nigeria. These guidelines were recently approved by the Nigerian Family Ministry of Health after they convened a technical expert meeting.
The inclusion of misoprostol in the country's official clinical guidelines is a fundamental step towards ensuring that misoprostol is used at the facility level to control postpartum hemorrhage - excessive bleeding after childbirth.
Dissemination and sensitization on the newly approved clinical guidelines have begun for health care professionals throughout the country. These sensitization efforts are coinciding with ongoing training efforts to familiarize health care providers with Active Management of Third Stage Labor and the Judicious use of Misoprostol and distribution activities of the local distributor, Emzor.
Links:
Trainings completed - over 225 healthcare providers trained to administer misoprostol for PPH
By Amy Grossman - Communications Manager, June 20, 2007 04:45 PM
In May 2007, Venture Strategies, in collaboration with our local partner Hygeia Nigeria Limited Foundation and under the guidance of Dr. Olawale Lawal Oyeneyin, completed training workshops on reducing maternal mortality and morbidity through Active Management of Third Stage of Labor (AMTSL) and the judicious use of misoprostol for the treatment of postpartum hemorrhage (PPH) in three key regions of the country: Lagos, Abuja, and Port Harcourt. In all, 228 healthcare providers, ranging from matrons and nurse midwives to MDs and medical directors were trained on AMTSL and the administration of misoprostol.
Pairs of one-day trainings were launched in February 2007 in Lagos which was attended by over 70 health professionals and the final trainings in Port Harcourt were held last month and attended by nearly 80 health care providers. Attendees represented the breadth of health facilities in the Hygeia Health Maintenance Organization’s extensive provider network. The trainings underscore the importance of misoprostol as an integral strategy to reduce maternal mortality. Primary objectives of the trainings were to improve the knowledge and attitude of health care workers in AMTSL and use of misoprostol, to increase the practice of AMTSL and use of misoprostol by healthcare workers at target facilities, and finally to empower trainees to become trainers themselves.
Venture Strategies is initiating the monitoring and evaluation phase of the AMTSL trainings, summer 2007.
Links:
Over 70 Nigerian health professionals reached in initial misoprostol training
By Melodie Holden - Vice President, March 20, 2007 05:50 PM
Lagos, Nigeria
Following our success in gaining the world's first regulatory approval of misoprostol for controlling postpartum hemorrhage (PPH), Venture Strategies, in collaboration with our local partner Hygeia Limited Foundation and under the guidance of Dr. Olawale Lawal Oyeneyin, has initiated several widely attended training workshops in Nigeria on reducing maternal mortality and morbidity. The workshops focus on the Active Management of Third Stage of Labor (AMTSL) and the judicious use of misoprostol for the treatment of PPH.
In Nigeria, pairs of one-day trainings are slated to be held in three major regions: Lagos, Abuja, and Port Harcourt. The two one-day trainings launched in February 2007 in Lagos was attended by over 70 health professionals ranging from matrons and nurse midwives to MDs and medical directors. Attendees represented the breadth of health facilities in the Hygeia Health Maintenance Organization’s extensive provider network, including Lagoon Clinic; the Salvation Army; and Alimosho, Mercy-Thomas Oredugba, Molabi, St. Sinai, St. Josephs Catholic, and Uwemedimo Hospitals to name but a few. Trainings in Abuja and Port Harcourt are slated for March and May of 2007, respectively.
The trainings underscore the importance of misoprostol as an integral strategy to reduce maternal mortality. Primary objectives of the trainings are to improve the knowledge and attitude of healthcare workers in AMTSL and use of misoprostol, to increase the practice of AMTSL and use of misoprostol by healthcare workers at target facilities, and finally to empower trainees to become trainers themselves.
For more information on our work visit:
Links:
Nigeria approves misopostol for controlling PPH
By Melodie Holden - Director of Operations, Venture Strategies, April 19, 2006 04:21 PM
An old drug will gain a new use in Nigeria this week when misoprostol will be distributed for prevention and control of post-partum hemorrhage, the life-threatening bleeding after childbirth that commonly occurs in developing countries.
Our non-profit organization, Venture Strategies for Health and Development, worked with UC Berkeley's School of Public Health to help Nigerian colleagues obtain the world's first regulatory approval of misoprostol for controlling postpartum hemorrhage, the leading cause of maternal death.
UC Berkeley issued a press release which was picked up by several news agencies. Please visit our web site to read the full story (link below).
We have obtained the lowest prices in the world from high quality manufacturers in China and Egypt and are helping to facilitate the type of South-South trade established in Nigeria with other countries in Africa and the Middle East, at their request.
If you would like to read more about our misoprostol projects and related publications, we invite you to see our web site (link below).
Links:
|
